Inclusion Criteria:  Ability to understand and voluntarily agrees to participate by giving written informed consent for the study; Male or female aged ≥18 years and ≤70 years at the time of signing the ICF; Histopathologically or cytologically documented advanced or metastatic malignancies; An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; Life expectancy ≥12 weeks; Adequate organ functions as defined; Female and male patients of reproductive potential must agree to use highly effective contraception during the study treatment period and within 6 months after the last investigational drug administration; Female of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before the first dose of the investigational drugs and must not be breastfeeding.  Exclusion Criteria:  Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis; Patients with active brain metastasis (without medical control or with clinical symptoms), cancerous meningitis, spinal cord compression, or patients with a history of primary tumors of the central nervous system ; Patients with tumor-related pain that cannot be controlled as determined by the investigator; Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion; Systemic anti-tumor therapy within 28 days prior to the first dose of the study treatment; Surgical procedures requiring general anesthesia within 28 days prior to the first dose of the study treatment; Patients who have received >30 Gy of radical radiotherapy within 28 days before the first dose of study treatment; Unresolved CTCAE Grade >1 toxicity attributed to any prior anti-tumor therapy; Use of live attenuated vaccines within 28 days before the first dose of the study treatment; Patients who have received any systemic immunosuppressants within 14 days prior to the first dose of study treatment; Patients with interstitial pneumonitis or interstitial lung disease; past history of interstitial pneumonitis or interstitial lung disease requiring hormone therapy; History of autoimmune diseases; History of clinically significant bleeding symptom or bleeding tendency within 3 months before the first dose of study treatment; History of clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment; Evidence or history of arterial/venous thrombosis within 3 months before the first dose; Prior malignancy (other than current malignant tumor) within 5 ears before the first dose of study treatment; Known history of serious allergic reactions to the investigational product or its main ingredients; History of immunodeficiency; Presence of active hepatitis B or active hepatitis C; Severe infections within 4 weeks prior to the first study treatment; Evidence or history of active pulmonary tuberculosis within 1 year before study entry; any other conditions that are not suitable for participation in the study in the investigator's opinion.